Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis
March 01, 2022 07:00 ET
|
Gb Sciences
LAS VEGAS, March 01, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has been issued a new patent today by the...
Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment
February 01, 2022 07:00 ET
|
Gb Sciences
LAS VEGAS, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Following the promising study on cannabinoids and COVID-19 published by Oregon State University, Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-based...
Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility
January 11, 2022 07:54 ET
|
Gb Sciences
LAS VEGAS, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has closed the sale of its last...
Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives
December 06, 2021 07:00 ET
|
Gb Sciences
LAS VEGAS, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, a plant-based research and biopharma technology company, has reported positive results from a study of its potential treatment for cytokine...
Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships
November 29, 2021 07:00 ET
|
Gb Sciences
LAS VEGAS, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Recognizing the glacial pace of traditional drug research and development processes and the adverse effect of this on patients, biopharmaceutical company...
Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety
November 01, 2021 07:00 ET
|
Gb Sciences
LAS VEGAS, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. ("GbS"; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has initiated new preclinical...
Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation
September 14, 2021 07:00 ET
|
Gb Sciences
LAS VEGAS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB: GBLX) received positive proof-of-concept data from a human immune cell model supporting their proprietary...
Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference
September 09, 2021 09:54 ET
|
Gb Sciences
LAS VEGAS, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired biopharmaceutical development company, today announced that their President and Chief Science...